Royalty Pharma plc
RPRX
$35.42
$0.270.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 51.61% | 36.76% | -24.31% | 520.96% | 164.07% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | 13.22% | 4.97% | -4.57% | -9.01% | -12.01% |
| Total Other Non-Cash Items | -92.73% | -47.92% | 16.59% | -163.06% | -57.49% |
| Change in Net Operating Assets | 8.36% | 9.70% | -5.30% | -3.12% | -5.22% |
| Cash from Operations | -9.85% | 3.12% | -7.32% | 0.50% | -2.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 41.08% | -30.40% | -29.20% | -382.26% | -48.90% |
| Cash from Investing | 38.03% | -30.40% | -29.20% | -382.26% | -48.90% |
| Total Debt Issued | -100.00% | 320.35% | 320.35% | -- | -- |
| Total Debt Repaid | -- | -- | -- | 65.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -359.42% | -207.93% | 24.65% | 24.52% | -86.19% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -2.30% | -3.99% | -5.06% | -5.37% | -5.93% |
| Other Financing Activities | -1.28% | -8.47% | -3.77% | 9.02% | 12.51% |
| Cash from Financing | -214.27% | 82.88% | 116.81% | 117.74% | 38.58% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -177.34% | 121.61% | 136.64% | 124.65% | -727.97% |